Mu-Opioid Receptor and Alpha 2-adrenoceptor Agonist Binding Sites in the Postmortem Brain of Heroin Addicts

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 1994 Jun 1

PMID 7862885

Citations 11

Authors

A M Gabilondo

J J Meana

F Barturen

M Sastre

J A Garcia-Sevilla

Affiliations

Soon will be listed here.

Abstract

The biochemical status of human brain mu-opioid receptors and alpha 2-adrenoceptors during opiate dependence was studied by means of the binding of [3H] [D-Ala2, MePhe4, Gly-ol5] enkephalin (DAGO) and [3H]clonidine, respectively, in postmortem brains of heroin addicts who had died by opiate overdose or other causes. In the frontal cortex, thalamus and caudate of heroin addicts the density (Bmax) and affinity (KD) of mu-opioid receptors were similar to those in controls. In contrast, the density of alpha 2-adrenoceptors in heroin addicts was found to be significantly decreased in frontal cortex (Bmax 31% lower), hypothalamus (Bmax 40% lower) and caudate (Bmax 32% lower) without changes in KD values. When heroin addicts were divided into two subgroups according to the presence or absence of morphine in body fluids, only the group with positive screening for morphine showed relevant decreases in brain alpha 2-adrenoceptor density (Bmax 36-48% lower), whereas the decreases in receptor density observed in the subgroup with negative screening for morphine did not reach statistical significance. The results suggest that desensitization of brain alpha 2A-adrenceptors is a relevant adaptative receptor mechanism during opiate addiction in humans.

Citing Articles

Opioid modulation of prefrontal cortex cells and circuits.

Cole R, Moussawi K, Joffe M Neuropharmacology. 2024; 248:109891.

PMID: 38417545 PMC: 10939756. DOI: 10.1016/j.neuropharm.2024.109891.

Opioids and opioid receptors; understanding pharmacological mechanisms as a key to therapeutic advances and mitigation of the misuse crisis.

Lambert D BJA Open. 2023; 6:100141.

PMID: 37588171 PMC: 10430815. DOI: 10.1016/j.bjao.2023.100141.

Class A and C GPCR Dimers in Neurodegenerative Diseases.

Caniceiro A, Bueschbell B, Schiedel A, Moreira I Curr Neuropharmacol. 2022; 20(11):2081-2141.

PMID: 35339177 PMC: 9886835. DOI: 10.2174/1570159X20666220327221830.

Adult-Attention Deficit Hyperactive Disorder Symptoms Seem Not to Influence the Outcome of an Enhanced Agonist Opioid Treatment: A 30-Year Follow-Up.

Maremmani A, Rocco P, Della Rocca F, Perugi G, Miccoli M, Maremmani I Int J Environ Res Public Health. 2021; 18(20).

PMID: 34682744 PMC: 8535915. DOI: 10.3390/ijerph182010997.

Neuropathology of substance use disorders.

Cadet J, Bisagno V, Milroy C Acta Neuropathol. 2013; 127(1):91-107.

PMID: 24292887 PMC: 7453825. DOI: 10.1007/s00401-013-1221-7.

References

Duman R, Tallman J, Nestler E . Acute and chronic opiate-regulation of adenylate cyclase in brain: specific effects in locus coeruleus. J Pharmacol Exp Ther. 1988; 246(3):1033-9. View

Werling L, McMahon P, Cox B . Selective tolerance at mu and kappa opioid receptors modulating norepinephrine release in guinea pig cortex. J Pharmacol Exp Ther. 1988; 247(3):1103-6. View

Aghajanian G, Wang Y . Common alpha 2- and opiate effector mechanisms in the locus coeruleus: intracellular studies in brain slices. Neuropharmacology. 1987; 26(7B):793-9. DOI: 10.1016/0028-3908(87)90054-2. View

Delean A, Munson P, Rodbard D . Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978; 235(2):E97-102. DOI: 10.1152/ajpendo.1978.235.2.E97. View

Ulibarri I, Garcia-Sevilla J, Ugedo L . Modulation of brain alpha 2-adrenoceptor and mu-opioid receptor densities during morphine dependence and spontaneous withdrawal in rats. Naunyn Schmiedebergs Arch Pharmacol. 1987; 336(5):530-7. DOI: 10.1007/BF00169310. View

Werling L, McMahon P, Cox B . Selective changes in mu opioid receptor properties induced by chronic morphine exposure. Proc Natl Acad Sci U S A. 1989; 86(16):6393-7. PMC: 297846. DOI: 10.1073/pnas.86.16.6393. View

Lutfy K, Yoburn B . The role of opioid receptor density in morphine tolerance. J Pharmacol Exp Ther. 1991; 256(2):575-80. View

Raiteri M, Bonanno G, Maura G, Pende M, Andrioli G, Ruelle A . Subclassification of release-regulating alpha 2-autoreceptors in human brain cortex. Br J Pharmacol. 1992; 107(4):1146-51. PMC: 1907924. DOI: 10.1111/j.1476-5381.1992.tb13421.x. View

Van Vliet B, de Vries T, Wardeh G, Mulder A, Schoffelmeer A . mu-Opioid receptor-regulated adenylate cyclase activity in primary cultures of rat striatal neurons upon chronic morphine exposure. Eur J Pharmacol. 1991; 208(2):105-11. DOI: 10.1016/0922-4106(91)90060-u. View

10.

Charney D, Redmond Jr D, Galloway M, KLEBER H, Heninger G, Murberg M . Naltrexone precipitated opiate withdrawal in methadone addicted human subjects: evidence for noradrenergic hyperactivity. Life Sci. 1984; 35(12):1263-72. DOI: 10.1016/0024-3205(84)90097-3. View

11.

Collin E, Cesselin F . Neurobiological mechanisms of opioid tolerance and dependence. Clin Neuropharmacol. 1991; 14(6):465-88. DOI: 10.1097/00002826-199112000-00001. View

12.

Korf J, Bunney B, Aghajanian G . Noradrenergic neurons: morphine inhibition of spontaneous activity. Eur J Pharmacol. 1974; 25(2):165-9. DOI: 10.1016/0014-2999(74)90045-4. View

13.

Garcia-Sevilla J, Ulibarri I, Ugedo L, Gutierrez M . Alpha 2-adrenoceptor-mediated inhibition of platelet adenylate cyclase activity in heroin addicts in abstinence. Psychopharmacology (Berl). 1987; 92(3):320-3. DOI: 10.1007/BF00210837. View

14.

Nestler E, Erdos J, Terwilliger R, Duman R, Tallman J . Regulation of G proteins by chronic morphine in the rat locus coeruleus. Brain Res. 1989; 476(2):230-9. DOI: 10.1016/0006-8993(89)91243-2. View

15.

Nestler E . Molecular mechanisms of drug addiction. J Neurosci. 1992; 12(7):2439-50. PMC: 6575828. View

16.

HAMBURG M, Tallman J . Chronic morphine administration increases the apparent number of alpha 2-adrenergic receptors in rat brain. Nature. 1981; 291(5815):493-5. DOI: 10.1038/291493a0. View

17.

Garcia-Sevilla J, Ugedo L, Ulibarri I, Gutierrez M . Platelet alpha 2-adrenoceptors in heroin addicts during withdrawal and after treatment with clonidine. Eur J Pharmacol. 1985; 114(3):365-74. DOI: 10.1016/0014-2999(85)90382-6. View

18.

Petrash A, Bylund D . Alpha-2 adrenergic receptor subtypes indicated by [3H]yohimbine binding in human brain. Life Sci. 1986; 38(23):2129-37. DOI: 10.1016/0024-3205(86)90212-2. View

19.

Munson P, Rodbard D . Ligand: a versatile computerized approach for characterization of ligand-binding systems. Anal Biochem. 1980; 107(1):220-39. DOI: 10.1016/0003-2697(80)90515-1. View

20.

Aghajanian G . Tolerance of locus coeruleus neurones to morphine and suppression of withdrawal response by clonidine. Nature. 1978; 276(5684):186-8. DOI: 10.1038/276186a0. View